Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Denis Soulières, Jose Luis Aguilar, Eric Chen, Krzysztof Misiukiewicz, Scott Ernst, Hyun Jung Lee, Katherine Bryant, Shuang He, Coleman K Obasaju, Shao-Chun Chang, Steve Chin, Douglas Adkins, Denis Soulières, Jose Luis Aguilar, Eric Chen, Krzysztof Misiukiewicz, Scott Ernst, Hyun Jung Lee, Katherine Bryant, Shuang He, Coleman K Obasaju, Shao-Chun Chang, Steve Chin, Douglas Adkins

Abstract

Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab manufactured by ImClone (US commercial cetuximab) potentially results in higher systemic exposures than cetuximab manufactured by Boehringer Ingelheim (BI-manufactured cetuximab). This prospective, randomized, double-blind study compared the safety profiles of the two cetuximab formulations.

Methods: Patients with previously untreated locoregionally recurrent and/or metastatic SCCHN were randomly assigned to receive the same dose of US commercial cetuximab (Arm A) or BI-manufactured cetuximab (Arm B), each in combination with cisplatin or carboplatin plus 5-FU. The primary outcome was all-grade, all-cause treatment-emergent adverse events (TEAEs).

Results: The majority of patients experienced ≥ 1 TEAE, regardless of causality (Arm A: 75/77 patients, 97.4%; Arm B: 68/71 patients, 95.8%). TEAEs with the highest incidence included nausea, fatigue, and hypomagnesemia in both arms. The absolute risk difference between the two arms for patients experiencing at least one adverse event (AE) was 0.029 (p = 0.281, 95% confidence interval [CI]: -0.024, 0.082) for AEs regardless of causality and 0.005 (p = 0.915, 95% CI: -0.092, 0.103) for AEs possibly related to study drug. There were no significant differences between the two arms in the incidence of acneiform rash, cardiac events, infusion reactions, or hypomagnesemia. Overall survival, progression-free survival, and overall response rates were similar in the two arms.

Conclusions: There were no clinically meaningful differences in safety between US commercial cetuximab and BI-manufactured cetuximab in combination with platinum-based therapy with 5-FU in patients with locoregionally recurrent and/or metastatic SCCHN. The use of US commercial cetuximab in this combination chemotherapy regimen did not result in any unexpected safety signals. The efficacy results of this study are consistent with the efficacy results of the cetuximab arm of the EXTREME study.

Trial registration: ClinicalTrials.gov NCT01081041 ; date of registration: March 3, 2010).

Figures

Fig. 1
Fig. 1
Patient flow. Abbreviations: BI = Boehringer Ingelheim; RT = randomized and treated; US = United States

References

    1. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–vii261.
    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancer. Version 2.2014. . Accessed 24 Nov 2014.
    1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127. doi: 10.1056/NEJMoa0802656.
    1. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–8654. doi: 10.1200/JCO.2005.02.4646.
    1. Erbitux Prescribing Information. Revised August 2013. Branchburg, NJ: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. . Accessed 11 Nov 2014.
    1. Erbitux Summary of Product Characteristics. Revised August 2014. Darmstadt, Germany: Merck KGaA. . Accessed 26 Nov 2014.
    1. A Study in Head and Neck Cancer. study record. . Accessed 27 Nov 2014.
    1. Platinol [product information]. Bristol-Myers Squibb Company 2010. . Accessed 11 Nov 2014.
    1. Carboplatin FDA Professional Drug Information. . Accessed 14 Nov 2016.
    1. Adrucil (Fluorouracil) Injection. TEVA Parenteral Medicines, Inc. . Accessed 11 Nov 2014.
    1. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866–2872. doi: 10.1200/JCO.2005.04.3547.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe